Pembrolizumab on pre-existing inclusion body myositis: a case report

Pembrolizumab on pre-existing inclusion body myositis: a case report

Abstract Background Cases of exacerbation of pre-existing neuromuscular diseases induced by immune checkpoint inhibitors (ICIs) have rarely been reported because patients with autoimmune diseases have generally been excluded from ICI therapy due to the increased risk of exacerbation. We describe the...

Full description

Bibliographic Details
Main Authors: Naohiro Uchio, Atsushi Unuma, Toshiyuki Kakumoto, Masao Osaki, Yoshitaka Zenke, Kenichi Sakuta, Akatsuki Kubota, Yoshikazu Uesaka, Tatsushi Toda, Jun Shimizu
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Rheumatology
Subjects:
Inclusion body myositis
Immune checkpoint
Pembrolizumab
Immune-related adverse events
Online Access:http://link.springer.com/article/10.1186/s41927-020-00144-5

Internet

http://link.springer.com/article/10.1186/s41927-020-00144-5

Similar Items